Metastatic adenocarcinoma of unknown primary origin

被引:65
|
作者
Hammar, SP [1 ]
机构
[1] Special Diagnost Lab, Bremerton, WA 98310 USA
关键词
metastatic; adenocarcinomas; neoplasms; unknown origin; electron microscopy; immunohistochemistry;
D O I
10.1016/S0046-8177(98)90007-7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Adenocarcinomas account for up to 60% of all metastatic neoplasms of unknown primary origin. In general, adenocarcinomas are the most difficult metastatic tumor to accurately identify the primary site. Some metastatic adenocarcinomas have distinctive histological features that allow for their site determination (eg colonic adenocarcinoma, bronchioloalveolar cell carcinoma), although the majority of metastatic adenocarcinomas have histological features that are not distinctive enough to allow for a specific diagnosis of their origin. For this reason, electron microscopy and immunohistochemistry have been used to help identify the exact type (origin) of metastatic adenocarcinomas. Relatively specific ultrastructural features used to diagnose metastatic adenocarcinomas of unknown primary origin include tubular myelin, intranuclear surfactant apoprotein tubular inclusions, Clara cell granules, uniform short microvilli with filamentous cores and core rootlets, Langerhans cells associated with neoplastic cells, cytoplasmic hyaline globules, lipid droplets, glycogen, and cytoplasmic crystals. Only a few of these ultrastructural features are absolutely specific. Relatively specific immunohistochemical tests used to diagnose metastatic adenocarcinomas of unknown primary origin include prostate-specific antigen, thyroglobulin, estrogen and progesterone receptor proteins, thyroid transcription factor-I, and surfactant apoproteins. Of these, prostate-specific antigen and thyroglobulin are the most specific. The purpose of this article is to discuss the use of electron microscopy and immunohistochemistry in the site-specific diagnosis of metastatic adenocarcinomas of unknown primary origin. HUM PATHOL 29:1393-1402. Copyright (C) 1998 by W.B. Saunders Company.
引用
收藏
页码:1393 / 1402
页数:10
相关论文
共 50 条
  • [41] HER-2/neu expression is consistent in primary and metastatic lung adenocarcinoma
    Fassan, Matteo
    Rea, Federico
    Pizzi, Marco
    Rugge, Massimo
    LUNG CANCER, 2011, 71 (03) : 371 - 372
  • [42] The Elusive Primary: Metastatic Adenocarcinoma of the Breast Presenting Solely as a Hard Sternal Mass
    Omar, Rozaliekah Mohd
    Ismail, Ilham Ameera
    Yasin, Mazapuspavina Md
    Affandi, Khairunisa Ahmad
    Hasbullah, Harissa Husainy
    Ali, Norliana Dalila Mohamad
    AMERICAN JOURNAL OF CASE REPORTS, 2023, 24
  • [43] A Long-term Survivor after Pancreaticoduodenectomy for Metastatic Undifferentiated Carcinoma of an Unknown Primary
    Nakagawa, Yuji
    Todoroki, Takeshi
    Morishita, Yukio
    Mori, Kennsaku
    Nakahaashi, Chigusa
    Ohkohchi, Nobuhiro
    Matsumoto, Hisashi
    HEPATO-GASTROENTEROLOGY, 2008, 55 (86-87) : 1557 - 1561
  • [44] Diagnostic strategies for unknown primary cancer
    Varadhachary, GR
    Abbruzzese, JL
    Lenzi, R
    CANCER, 2004, 100 (09) : 1776 - 1785
  • [45] Fine needle aspiration and core needle biopsy of metastatic malignancy of unknown primary site
    Elsheikh, Tarik M.
    Silverman, Jan F.
    MODERN PATHOLOGY, 2019, 32 : 58 - 70
  • [46] Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin - A retrospective study
    Katagiri, H
    Takahashi, M
    Inagaki, J
    Sugiura, H
    Ito, S
    Iwata, H
    CANCER, 1999, 86 (03) : 533 - 537
  • [47] Prognostic clinicopathologic factors in carcinoma of unknown primary origin: a study of 106 consecutive cases
    Choi, Junjeong
    Nahm, Ji Hae
    Kim, Sang Kyum
    ONCOTARGET, 2017, 8 (37) : 62630 - 62640
  • [48] New Strategies for Carcinoma of Unknown Primary: The Role of Tissue-of-Origin Molecular Profiling
    Varadhachary, Gauri
    CLINICAL CANCER RESEARCH, 2013, 19 (15) : 4027 - 4033
  • [49] Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study
    Westphalen, C. B.
    Federer-Gsponer, J.
    Pauli, C.
    Karapetyan, A. R.
    Chalabi, N.
    Duran-Pacheco, G.
    Beringer, A.
    Bochtler, T.
    Cook, N.
    Hoglander, E.
    Jin, D. X.
    Losa, F.
    Mileshkin, L.
    Moch, H.
    Ross, J. S.
    Sokol, E. S.
    Tothill, R. W.
    Kramer, A.
    ESMO OPEN, 2023, 8 (06)
  • [50] Gene-expression assays and personalized cancer care: tissue-of-origin test for cancer of unknown primary origin
    Takei, Hidehiro
    Monzon, Federico A.
    PERSONALIZED MEDICINE, 2011, 8 (04) : 429 - 436